With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes. These treatments can positively affect appetite, ...
New research has found that 50% of patients regain the weight they lost if they stop taking Wegovy and Zepbound There are two new weight-loss treatments in the U.S., and some patients are now ...
2don MSN
The rise of ‘agonorexia’: People are developing brand new eating disorders on GLP-1 agonist drugs
Welcome to The Thin Line, The New York Post’s series about the darker side of GLP-1 drugs. Though GLP-1 agonists sold under ...
ATLANTA — More than half of the people who stop using GLP-1 drugs regain at least some of the weight within a year, new real-world data showed. The new findings, from a large national claims database, ...
About 20 years ago, the U.S. Food and Drug Administration approved the first GLP-1 medication for Type 2 diabetes. Today, the landscape has shifted, as the agency has approved various ...
These drugs work by targeting GLP-1, a satiety hormone that has been sh… ...
News Medical on MSN
New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders
By Tarun Sai Lomte An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing ...
Tia Timmer was always “on the heavier side,” but her weight never held her back – until she had to keep up with two grandchildren.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results